Analysts at StockNews.com initiated coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Separately, BTIG Research decreased their target price on OncoSec Medical from $10.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, March 16th.
NASDAQ:ONCS opened at $0.86 on Wednesday. The firm has a market cap of $33.85 million, a PE ratio of -0.91 and a beta of 2.03. OncoSec Medical has a fifty-two week low of $0.67 and a fifty-two week high of $4.25. The business has a 50 day moving average price of $0.83 and a 200-day moving average price of $0.95.
Several institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC bought a new position in shares of OncoSec Medical during the third quarter valued at approximately $45,000. Salzhauer Michael raised its holdings in OncoSec Medical by 15.9% in the fourth quarter. Salzhauer Michael now owns 321,354 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 44,042 shares in the last quarter. Long Focus Capital Management LLC bought a new position in OncoSec Medical in the fourth quarter worth $66,000. Two Sigma Advisers LP raised its holdings in OncoSec Medical by 128.2% in the third quarter. Two Sigma Advisers LP now owns 361,401 shares of the biotechnology company’s stock worth $770,000 after purchasing an additional 203,010 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in OncoSec Medical by 653.7% in the first quarter. Bank of New York Mellon Corp now owns 386,074 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 334,849 shares in the last quarter. Institutional investors own 13.98% of the company’s stock.
About OncoSec Medical (Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.